Back

FORTIFY: a phase 2b randomised trial evaluating the effect of orticumab on coronary inflammation (FAI-Score) in post myocardial infarction patients selects for patients with high residual FAI-Score

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Mechanisms of microvascular injury: from neutrophils to no-reflow Inflammation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Todd Villines

University of Virginia, Charlottesville (United States of America)

5 More presentations in this session

Presentation thumbnail
Inclisiran alleviates myocardial ischemia/reperfusion injury by blocking the HIF-1a/Myo1d-mediated M1 differentiation of macrophages
Doctor L. Guo (Dalian, CN)
Abstract Slides
Presentation thumbnail
Gliflozin therapy attenuates persistent systemic inflammation and monocyte metabolic dysfunction post-ACS: a comparative study across the CAD spectrum
Doctor A. Mroueh (Strasbourg, FR)
Abstract Slides
Presentation thumbnail
Sex-dependent molecular signatures of reticulated platelets
Doctor S. Kuehne (Augsburg, DE)
Abstract Slides
Presentation thumbnail
Neutrophil abundance determines microvascular obstruction in endotoxemia
Mr T. Artner (Vienna, AT)
Abstract Slides
Presentation thumbnail
Histologic characteristics potentially associated with coronary vasospasm in myocardial infarction cases without apparent epicardial coronary culprit stenosis.
Professor T. Matsuyama (Tokyo, JP)
Abstract Slides

Access the full session

Session thumbnail
Mechanisms of microvascular injury: from neutrophils to no-reflow

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Standardised quantification of coronary inflammation using cardiac computed tomography: The Fat Attenuation Index Score (FAI-Score)
17 April 2021
thumbnail
Congress Presentation
Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody
1 September 2024
thumbnail
Congress Presentation
Inhibition of fractalkine signalling reduces intramyocardial haemorrhage and left ventricular thrombus in patients with acute myocardial infarction by modulating immunothrombosis (The FRACTAL trial)
1 September 2025
thumbnail
Congress Presentation
Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources